Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Guida

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
Journal of Translational Medicine|December 24, 2003
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialMichele Guida, Alessandra Ravaioli, Vanna Chiarion Sileni, et al.
Journal of Translational Medicine|December 11, 2020
Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanomaSabino Strippoli, Livia Fucci, Antonio Negri, et al.
Frontiers in Immunology|May 27, 2024
Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?Teresa Squicciarini, Rossella Villani, Benedetta Apollonio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trialRuggero Ridolfi, Vanna Chiarion-Sileni, Michele Guida, et al.
Journal of Environmental Radioactivity|February 3, 2026
Environmental and health risk assessment of radon in Capodifiume Lake: Investigating elevated radon levels in a karst aquifer systemMichele Guida, Simona Mancini, Serpil Akӧzcan Pehlivanoğlu, et al.
Journal for Immunotherapy of Cancer|May 11, 2021
uPAR<sup>+</sup> extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patientsLetizia Porcelli, Michele Guida, Simona De Summa, et al.
Journal of Translational Medicine|September 20, 2019
Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatmentPaolo Antonio Ascierto, Lorenzo Borgognoni, Gerardo Botti, et al.
Journal of Translational Medicine|August 16, 2019
New paradigm for stage III melanoma: from surgery to adjuvant treatmentPaolo Antonio Ascierto, Lorenzo Borgognoni, Gerardo Botti, et al.
Oncology Reports|November 8, 2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trialVito Lorusso, Vittorio Gebbia, Massimiliano Spada, et al.
Pigment Cell & Melanoma Research|August 20, 2016
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitorsMichele Guida, Sabino Strippoli, Anna Ferretta, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
Journal of Translational Medicine|December 24, 2003
Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trialMichele Guida, Alessandra Ravaioli, Vanna Chiarion Sileni, et al.
Journal of Translational Medicine|December 11, 2020
Cellular analysis of bronchoalveolar lavage fluid to narrow differential diagnosis of checkpoint inhibitor-related pneumonitis in metastatic melanomaSabino Strippoli, Livia Fucci, Antonio Negri, et al.
Frontiers in Immunology|May 27, 2024
Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?Teresa Squicciarini, Rossella Villani, Benedetta Apollonio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2002
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trialRuggero Ridolfi, Vanna Chiarion-Sileni, Michele Guida, et al.
Journal of Environmental Radioactivity|February 3, 2026
Environmental and health risk assessment of radon in Capodifiume Lake: Investigating elevated radon levels in a karst aquifer systemMichele Guida, Simona Mancini, Serpil Akӧzcan Pehlivanoğlu, et al.
Journal for Immunotherapy of Cancer|May 11, 2021
uPAR<sup>+</sup> extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patientsLetizia Porcelli, Michele Guida, Simona De Summa, et al.
Journal of Translational Medicine|September 20, 2019
Correction to: New paradigm for stage III melanoma: from surgery to adjuvant treatmentPaolo Antonio Ascierto, Lorenzo Borgognoni, Gerardo Botti, et al.
Journal of Translational Medicine|August 16, 2019
New paradigm for stage III melanoma: from surgery to adjuvant treatmentPaolo Antonio Ascierto, Lorenzo Borgognoni, Gerardo Botti, et al.
Oncology Reports|November 8, 2005
Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trialVito Lorusso, Vittorio Gebbia, Massimiliano Spada, et al.
Pigment Cell & Melanoma Research|August 20, 2016
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitorsMichele Guida, Sabino Strippoli, Anna Ferretta, et al.
Pageof 13